WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In an imatinib-treated patient with CML who was administered a WT1 peptide vaccine, a decrease in BCR-ABL mRNA levels was associated with an increased frequency of WT1-specific CTLs in the patient’s peripheral blood [43].